Dose-Response Relationship, Immunologic
"Dose-Response Relationship, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.
| Descriptor ID |
D004306
|
| MeSH Number(s) |
G12.300
|
| Concept/Terms |
Dose-Response Relationship, Immunologic- Dose-Response Relationship, Immunologic
- Dose Response Relationship, Immunologic
- Immunologic Dose-Response Relationship
- Dose-Response Relationships, Immunologic
- Immunologic Dose Response Relationship
- Immunologic Dose-Response Relationships
- Relationships, Immunologic Dose-Response
- Relationship, Immunologic Dose-Response
- Relationship, Immunologic Dose Response
|
Below are MeSH descriptors whose meaning is more general than "Dose-Response Relationship, Immunologic".
Below are MeSH descriptors whose meaning is more specific than "Dose-Response Relationship, Immunologic".
This graph shows the total number of publications written about "Dose-Response Relationship, Immunologic" by people in this website by year, and whether "Dose-Response Relationship, Immunologic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dose-Response Relationship, Immunologic" by people in Profiles.
-
Induction of lymphotoxin-alpha by interleukin-12 p40 homodimer, the so-called biologically inactive molecule, but not IL-12 p70. Immunology. 2009 Jul; 127(3):312-25.
-
Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol. 2003 May 15; 170(10):4905-13.
-
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol. 2001 Jan 01; 19(1):145-56.
-
Differential effects of CD28 costimulation on HIV production by CD4+ cells. J Immunol. 1998 Dec 01; 161(11):6223-7.
-
Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection. Invest Ophthalmol Vis Sci. 1997 Jun; 38(7):1418-25.
-
Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum. 1996 Feb; 39(2):257-65.
-
Development of an anti-idiotype monoclonal antibody mimicking the structure of lipopolysaccharide (LPS) inner-core determinants. Microb Pathog. 1993 Aug; 15(2):103-20.
-
Antibacterial and protective properties of monoclonal antibodies reactive with Escherichia coli O111:B4 lipopolysaccharide: relation to antibody isotype and complement-fixing activity. J Infect Dis. 1992 Jan; 165(1):34-45.
-
Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res. 1991 Jan 01; 51(1):144-9.
-
Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo beta-interferon. Clin Exp Immunol. 1987 Jul; 69(1):107-15.